A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.

MLA

Tie Zhou, et al. “A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer.” PLoS ONE, vol. 10, no. 1, Jan. 2015, p. e0117002. EBSCOhost, https://doi.org/10.1371/journal.pone.0117002.

APA

Tie Zhou, Shu-xiong Zeng, Ding-wei Ye, Qiang Wei, Xu Zhang, Yi-ran Huang, Zhang-qun Ye, Yong Yang, Wei Zhang, Ye Tian, Fang-jian Zhou, Jin Jie, Shi-ping Chen, Yan Sun, Li-ping Xie, Xing Yao, Yan-qun Na, & Ying-hao Sun. (2015). A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer. PLoS ONE, 10(1), e0117002. https://doi.org/10.1371/journal.pone.0117002

Chicago

Tie Zhou, Shu-xiong Zeng, Ding-wei Ye, Qiang Wei, Xu Zhang, Yi-ran Huang, Zhang-qun Ye, et al. 2015. “A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer.” PLoS ONE 10 (1): e0117002. doi:10.1371/journal.pone.0117002.